

# CITATION REPORT

List of articles citing

**A pilot trial of *Saccharomyces boulardii* in ulcerative colitis**

**DOI: 10.1097/00042737-200306000-00017**

**European Journal of Gastroenterology and Hepatology  
, 2003, 15, 697-8.**

**Source:** <https://exaly.com/paper-pdf/36034664/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
290	Probiotics for the maintenance of remission in Crohn's disease. <b>2004</b> ,		3
289	Probiotics and the management of inflammatory bowel disease. <b>2004</b> , 10, 286-99		129
288	Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. <b>2004</b> , 126, 1620-33		808
287	Current therapy of ulcerative colitis in children. <b>2004</b> , 5, 37-53		9
286	Screening of dairy yeast strains for probiotic applications. <b>2004</b> , 87, 4050-6		140
285	Bibliography. Current world literature. Gastrointestinal infections. <b>2004</b> , 20, 49-60		
284	Bibliography. Current world literature. Inflammatory bowel disease. <b>2004</b> , 20, 404-22		
283	Bibliography. Current world literature. Small intestine. <b>2004</b> , 20, 168-76		
282	Probiotics and prebiotics in gastrointestinal disorders. <b>2004</b> , 20, 146-55		90
281	Commensal bacteria in the gut: learning who our friends are. <b>2004</b> , 20, 565-71		77
280	[Probiotics in inflammatory bowel disease: controlled trials and perspectives]. <b>2004</b> , 59, 83-7		3
279	Place of probiotics. <b>2005</b> , 11, 318-25		16
278	Probiotics used in human studies. <b>2005</b> , 39, 469-84		42
277	A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. <b>2005</b> , 11, 833-9		250
276	Complementary and alternative medicine in inflammatory bowel disease: keeping an open mind. <b>2005</b> , 1, 277-92		2
275	VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, 1539-46	0.7	551
274	The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics. <b>2005</b> , 34, 465-82, ix		38

273	Saccharomyces boulardii: basic science and clinical applications in gastroenterology. <b>2005</b> , 34, 515-32, x		22
272	Probiotics and nutraceuticals: non-medicinal treatments of gastrointestinal diseases. <b>2005</b> , 5, 596-603		96
271	Use of probiotics in humans: an analysis of the literature. <b>2005</b> , 34, 547-70, x		35
270	Probiotics in Inflammatory Bowel Disease. <b>2006</b> , 17, 55-60		
269	Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. <b>2006</b> , 131, 1812-25		116
268	VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases. <b>2006</b> , 66, 1371-87		81
267	Gastrointestinal microflora: probiotics. <i>Advances in Applied Microbiology</i> , <b>2006</b> , 59, 187-219	4.9	22
266	Safe and efficacious probiotics: what are they?. <b>2006</b> , 14, 348-52		50
265	Antibiotics and probiotics in treatment of inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , <b>2006</b> , 12, 3306-13	5.6	95
264	Probiotics and the gastrointestinal tract: where are we in 2005?. <i>World Journal of Gastroenterology</i> , <b>2006</b> , 12, 853-7	5.6	33
263	Probiotics and prebiotics in chronic inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , <b>2006</b> , 12, 5941-50	5.6	113
262	Probiotics. <b>2006</b> , 207-223		1
261	Immune Modulation by the Intestinal Microbiota. <b>2006</b> , 93-122		
260	Probiotics and bowel inflammation. <b>2006</b> , 247, 1-4		
259	Clinical efficacy of probiotics: review of the evidence with focus on children. <b>2006</b> , 43, 550-7		70
258	Probiotics in the treatment of inflammatory bowel disease. <b>2006</b> , 40, 260-3		67
257	Recommendations for probiotic use. <b>2006</b> , 40, 275-8		49
256	Probiotics for induction of remission in ulcerative colitis. <b>2006</b> ,		1

255	Synbiotic therapy: a promising new adjunctive therapy for ulcerative colitis. <b>2006</b> , 64, 132-8		9
254	Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 24 Suppl 3, 11-8	6.1	128
253	Evolving knowledge and therapy of inflammatory bowel disease. <b>2006</b> , 5, 197-209		141
252	Probiotics: do they help to control intestinal inflammation?. <b>2006</b> , 1072, 339-50		21
251	Effects of <i>Saccharomyces boulardii</i> on intestinal mucosa. <b>2006</b> , 51, 1485-92		81
250	The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease. <b>2006</b> , 8, 486-98		37
249	Probiotics for maintenance of remission in Crohn's disease. <b>2006</b> , CD004826		95
248	Are probiotics effective for treating <i>Clostridium difficile</i> disease and antibiotic-associated diarrhea?. <b>2006</b> , 3, 606-7		6
247	Drug therapy of inflammatory bowel disease in fertile women. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, S633-9	0.7	8
246	Probiotics in the Management of Inflammatory Bowel Diseases?. <i>American Journal of Gastroenterology</i> , <b>2007</b> , 102, S22-S28	0.7	3
245	Probiotics, prebiotics, and inflammatory bowel disease. <b>2007</b> , 90-116		1
244	Nutritional value of yoghurt. <b>2007</b> , 646-684		
243	Probiotics for induction of remission in ulcerative colitis. <b>2007</b> , CD005573		97
242	Prebiotics, probiotics, and dietary fiber in gastrointestinal disease. <b>2007</b> , 36, 47-63, v		50
241	<i>Saccharomyces boulardii</i> decreases inflammation and intestinal colonization by <i>Candida albicans</i> in a mouse model of chemically-induced colitis. <b>2007</b> , 45, 691-700		79
240	[Probiotics and prebiotics in inflammatory bowel disease]. <b>2007</b> , 30, 419-25		1
239	Modulation of neuroimmune axis and treatment of gastrointestinal diseases. <b>2007</b> , 4, 177-182		
238	Functional Foods and Gastrointestinal Disorders. 153-174		

237	Drug therapy for inflammatory bowel disease in pregnancy and the puerperium. <b>2007</b> , 21, 835-47		23
236	Review article: yeast as probiotics -- <i>Saccharomyces boulardii</i> . <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 26, 767-78	6.1	322
235	Review article: Probiotics in gastrointestinal and liver diseases. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2007</b> , 26 Suppl 2, 133-48	6.1	56
234	Probiotics and prebiotics ¶renaissance of a therapeutic principle. <b>2007</b> , 2, 237-270		22
233	The role of probiotics in inflammatory bowel disease. <b>2007</b> , 52, 607-11		29
232	<i>Clostridium butyricum</i> TO-A culture supernatant downregulates TLR4 in human colonic epithelial cells. <b>2007</b> , 52, 2963-71		26
231	Probiotics in the management of colonic disorders. <b>2007</b> , 9, 434-40		18
230	Increased intestinal delivery of viable <i>Saccharomyces boulardii</i> by encapsulation in microspheres. <b>2008</b> , 25, 1290-6		62
229	Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease?. <b>2008</b> , 52, 906-12		27
228	Role of probiotic therapy in IBD. <b>2008</b> , 14, 1597-605		70
227	Probiotics, prebiotics, and synbiotics. <b>2008</b> , 111, 1-66		395
226	Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 28, 815-29	6.1	14
225	Probiotics and prebiotics in inflammatory bowel disease: microflora ¶n the scope¶ <b>2008</b> , 65, 453-67		100
224	European evidence-based Consensus on the management of ulcerative colitis: Special situations. <b>2008</b> , 2, 63-92		165
223	An experimental study on ulcerative colitis as a potential target for probiotic therapy by <i>Lactobacillus acidophilus</i> with or without "olsalazine". <b>2008</b> , 2, 296-303		21
222	A review of complementary and alternative approaches to immunomodulation. <b>2008</b> , 23, 49-62		74
221	Probiotics in clinical practice: an overview. <b>2008</b> , 36 Suppl 1, 1A-53A		49
220	Integrative medicine in gastrointestinal disease: evaluating the evidence. <b>2008</b> , 2, 261-80		8

219	Rationale for probiotic treatment strategies in inflammatory bowel disease. <b>2008</b> , 2, 337-55		15
218	Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease. <b>2008</b> , 12, 301-12		16
217	<i>Saccharomyces boulardii</i> ameliorates <i>Citrobacter rodentium</i> -induced colitis through actions on bacterial virulence factors. <b>2008</b> , 294, G295-306		86
216	Formulations for protecting the probiotic <i>Saccharomyces boulardii</i> from degradation in acidic condition. <b>2008</b> , 31, 266-72		21
215	Probiotics for maintenance of remission in ulcerative colitis. <b>2008</b> ,		2
214	Manipulation of intestinal microbial flora for therapeutic benefit in inflammatory bowel diseases: review of clinical trials of probiotics, pre-biotics and synbiotics. <b>2008</b> , 3, 167-84		29
213	Probiotics for prevention of antibiotic-associated diarrhea. <b>2008</b> , 42 Suppl 2, S58-63		75
212	Probiotics in the treatment of human inflammatory bowel diseases: update 2008. <b>2008</b> , 42 Suppl 2, S97-103		25
211	Influence of pH conditions on the viability of <i>Saccharomyces boulardii</i> yeast. <b>2008</b> , 54, 221-7		32
210	Probiotic products in Canada with clinical evidence: what can gastroenterologists recommend?. <b>2008</b> , 22, 169-75		7
209	Treatment of inflammatory bowel disease: a review of medical therapy. <i>World Journal of Gastroenterology</i> , <b>2008</b> , 14, 354-77	5.6	163
208	Probiotics: sorting the evidence from the myths. <b>2008</b> , 188, 304-8		49
207	Probiotics in GI Diseases. <b>2009</b> , 126-134		1
206	Probiotics, immune function, infection and inflammation: a review of the evidence from studies conducted in humans. <i>Current Pharmaceutical Design</i> , <b>2009</b> , 15, 1428-518	3.3	155
205	Probiotics for inflammatory bowel disease: a critical appraisal. <b>2009</b> , 27 Suppl 1, 111-4		7
204	The therapeutic impact of manipulating microbiota in inflammatory bowel disease. <i>Current Pharmaceutical Design</i> , <b>2009</b> , 15, 2074-86	3.3	24
203	Bacteriotherapy for inflammatory bowel disease: therapeutic tool and/or pharmacological vectors?. <b>2009</b> , 33 Suppl 3, S228-34		10
202	Therapeutic strategies for the management of ulcerative colitis. <b>2009</b> , 15, 935-50		56

201	Prevention of TNBS-induced colitis by different Lactobacillus and Bifidobacterium strains is associated with an expansion of gammadeltaT and regulatory T cells of intestinal intraepithelial lymphocytes. <b>2009</b> , 15, 1526-36		90
200	Twenty-five years of research on Saccharomyces boulardii trophic effects: updates and perspectives. <b>2009</b> , 54, 15-8		56
199	The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea. <b>2009</b> , 26, 350-7		24
198	Probiotics in pediatric inflammatory bowel diseases. <b>2009</b> , 11, 238-47		2
197	Review article: anti-inflammatory mechanisms of action of Saccharomyces boulardii. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2009</b> , 30, 826-33	6.1	99
196	Saccharomyces boulardii inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation. <b>2009</b> , 156, 78-87		46
195	Emerging drugs for the treatment of ulcerative colitis. <b>2009</b> , 14, 505-21		19
194	Intestinal bacteria and inflammatory bowel disease. <b>2009</b> , 46, 25-54		67
193	Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 437-43	0.7	365
192	The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. <b>2009</b> , 7, 1202-9, 1209.e1		350
191	Clinical evidence for immunomodulatory effects of probiotic bacteria. <b>2009</b> , 48, 126-41		46
190	14 Probiotische Hefen. <b>2009</b> ,		
189	21 Probiotika zur Prophylaxe und Therapie chronisch entzündlicher Darmerkrankungen. <b>2009</b> ,		
188	Beneficial effects of probiotic and food borne yeasts on human health. <i>Nutrients</i> , <b>2010</b> , 2, 449-73	6.7	147
187	Probiotics. <b>2010</b> , 67, 449-58		212
186	The use of probiotics in gastrointestinal diseases. <b>2010</b> , 3, 105-113		7
185	Proinflammatory and anti-inflammatory cytokines present in the acute phase of experimental colitis treated with Saccharomyces boulardii. <b>2010</b> , 55, 2498-504		6
184	Progrès récents dans la recherche sur Saccharomyces boulardii. <b>2010</b> , 34, 67-75		

183	[Recent advances in <i>Saccharomyces boulardii</i> research]. <b>2010</b> , 34 Suppl 1, S62-70		22
182	Impact of probiotic supplementation on mortality of induced 1,2-dimethylhydrazine carcinogenesis in a mouse model. <b>2010</b> , 26, 779-83		5
181	Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered <i>Escherichia coli</i> Nissle 1917 (EcN). <b>2010</b> , 10, 13		128
180	The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models. <b>2010</b> , 8, 564-77		266
179	Probiotic Treatment of Colitis in Animal Models and People. <b>2010</b> , 571-587		
178	Probiotic yeasts: anti-inflammatory potential of various non-pathogenic strains in experimental colitis in mice. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 2134-45	5.6	58
177	Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 2218-27	0.7	320
176	Probiotics in gastrointestinal disorders. <b>2010</b> , 38, 122-9		15
175	Role of the gut microbiota in defining human health. <b>2010</b> , 8, 435-54		265
174	Systematic review and meta-analysis of <i>Saccharomyces boulardii</i> in adult patients. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 2202-22	5.6	303
173	Molecular crosstalk of probiotic bacteria with the intestinal immune system: clinical relevance in the context of inflammatory bowel disease. <b>2010</b> , 300, 63-73		75
172	[Microbiota and probiotics: effects on human health]. <b>2010</b> , 56, 611-50		10
171	Rozpoznawanie i leczenie mikroskopowego zapalenia jelita grubego z obecnościami makrofagów piankowatych u dzieci. <b>2011</b> , 86, 588-595		
170	Treatment of inflammatory bowel disease (IBD). <b>2011</b> , 63, 629-42		190
169	Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study. <b>2011</b> , 84, 128-33		134
168	Improving the Stress Tolerance of Probiotic Cultures: Recent Trends and Future Directions. <b>2011</b> , 395-438		11
167	Probiotics in the treatment of human inflammatory bowel diseases: update 2011. <b>2011</b> , 45 Suppl, S139-44		64
166	Current and Future Applications of Probiotics. <b>2011</b> , 7, 170-180		2



165	Regulation of the IL-10/IL-12 axis in human dendritic cells with probiotic bacteria. <b>2011</b> , 63, 93-107		45
164	Brewer's yeast cell wall affects microbiota composition and decreases <i>Bacteroides fragilis</i> populations in an anaerobic gut intestinal model. <b>2011</b> , 111, 178-84		5
163	Ulcerative Colitis in Children and Adolescents. <b>2011</b> , 490-504.e6		
162	Gut microbiota, probiotics and inflammatory bowel disease. <b>2011</b> , 59, 161-77		33
161	Inflammatory Bowel Disease. <b>2011</b> ,		2
160	Diagnosis and therapy of microscopic colitis with presence of foamy macrophages in children. <b>2011</b> , 2011, 756292		2
159	Anti-inflammatory effects of <i>Saccharomyces boulardii</i> mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis. <b>2011</b> , 301, G1083-92		38
158	Is 5-ASA still the treatment of choice for ulcerative colitis?. <b>2011</b> , 12, 1396-405		20
157	The Impact of Gut Microbiota in Human Health and Diseases: Implication for Therapeutic Potential. <b>2011</b> , 19, 155-173		3
156	The interplay between the gut immune system and microbiota in health and disease: nutraceutical intervention for restoring intestinal homeostasis. <i>Current Pharmaceutical Design</i> , <b>2013</b> , 19, 1329-42	3-3	67
155	Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. <b>2012</b> , 55, 340-61		265
154	Probiotic bacteria in the prevention and the treatment of inflammatory bowel disease. <b>2012</b> , 41, 821-42		20
153	Probiotic-induced apoptosis and its potential relevance to mucosal inflammation of gastrointestinal tract. <b>2012</b> , 57, 175-82		8
152	Efficacy and safety of the probiotic <i>Saccharomyces boulardii</i> for the prevention and therapy of gastrointestinal disorders. <i>Therapeutic Advances in Gastroenterology</i> , <b>2012</b> , 5, 111-25	4-7	173
151	Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. <b>2012</b> , 72, 803-23		156
150	<i>Saccharomyces boulardii</i> improves intestinal epithelial cell restitution by inhibiting $\alpha 5 \beta 1$ integrin activation state. <i>PLoS ONE</i> , <b>2012</b> , 7, e45047	3-7	20
149	Effect of incorporating prebiotics in coating materials for the microencapsulation of <i>Saccharomyces boulardii</i> . <i>International Journal of Food Sciences and Nutrition</i> , <b>2012</b> , 63, 930-5	3-7	15
148	Effectiveness of <i>Saccharomyces boulardii</i> in a rat model of colitis. <i>World Journal of Gastroenterology</i> , <b>2012</b> , 18, 6452-60; discussion p. 6459	5.6	17

147	[Not Available]. <b>2012</b> , 41, 123-33		1
146	Probiotics for the treatment of inflammatory bowel disease. <b>2012</b> , 14, 324-33		80
145	Manipulating the Indigenous Microbiota in Humans: Prebiotics, Probiotics, and Synbiotics. <b>2013</b> , 315-338		2
144	The role of probiotics and prebiotics in inducing gut immunity. <b>2013</b> , 4, 445		146
143	Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or <i>Saccharomyces boulardii</i> . <b>2013</b> , 50, 304-9		10
142	Effect of probiotics on the development of dimethylhydrazine-induced preneoplastic lesions in the mice colon. <b>2013</b> , 28, 367-72		17
141	Actual concept of "probiotics": is it more functional to science or business?. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 1527-40	5.6	38
140	Probiotic yeast inhibits VEGFR signaling and angiogenesis in intestinal inflammation. <i>PLoS ONE</i> , <b>2013</b> , 8, e64227	3.7	42
139	Microorganisms with claimed probiotic properties: an overview of recent literature. <b>2014</b> , 11, 4745-67		437
138	Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 11505-24	5.6	123
137	Roundoc Rx: Optimal Integrative Treatment for Ulcerative Colitis. <b>2014</b> , 20, 167-175		
136	Probiotics and antibiotics in IBD. <b>2014</b> , 32 Suppl 1, 10-7		33
135	[Nutrition and IBD-Consensus of the Austrian Working Group of IBD (Inflammatory Bowel Diseases) of the ÖGH]. <b>2014</b> , 52, 376-86		8
134	Cytokine and clinical response to <i>Saccharomyces boulardii</i> therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2014</b> , 26, 630-9	2.2	53
133	Gut microbiota and inflammatory bowel disease: the role of antibiotics in disease management. <b>2014</b> , 126, 7-19		192
132	Enhanced viability of probiotic <i>Saccharomyces boulardii</i> encapsulated by layer-by-layer approach in pH responsive chitosan-dextran sulfate polyelectrolytes. <b>2014</b> , 136, 1-8		31
131	<i>Saccharomyces boulardii</i> CNCM I-745 in different clinical conditions. <b>2014</b> , 14, 1593-609		34
130	Ability of synbiotic encapsulated <i>Saccharomyces cerevisiae</i> <i>boulardii</i> to grow in berry juice and to survive under simulated gastrointestinal conditions. <b>2014</b> , 31, 299-305		24

129	Intestinal microbiota pathogenesis and fecal microbiota transplantation for inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 14805-20	5.6	74
128	Commensal Intestinal Microbiota and Mucosal Immune System Development and Function. <b>2014</b> ,		
127	Inflammatory Bowel Disease. <b>2015</b> , 347-374		
126	Effect of <i>Saccharomyces cerevisiae</i> strain UFMG A-905 in experimental model of inflammatory bowel disease. <b>2015</b> , 6, 807-15		23
125	<i>Bifidobacterium longum</i> subsp. <i>infantis</i> BB-02 attenuates acute murine experimental model of inflammatory bowel disease. <b>2015</b> , 6, 277-86		21
124	Knowledge, use and perceptions of probiotics and prebiotics in hospitalised patients. <b>2015</b> , 72, 261-266		22
123	Probiotics in the Management of Ulcerative Colitis. <b>2015</b> , 49 Suppl 1, S50-5		39
122	Probiotic-based strategies for therapeutic and prophylactic use against multiple gastrointestinal diseases. <i>Frontiers in Microbiology</i> , <b>2015</b> , 6, 685	5.7	91
121	Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis. <i>Current Pharmaceutical Design</i> , <b>2016</b> , 22, 180-8	3.3	24
120	Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children. <b>2015</b> , 30, 747-59		21
119	The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy. <b>2015</b> , 149, 191-212		110
118	Intestinales Mikrobiom und chronisch-entzündliche Darmerkrankungen: Feindschaft oder Freundschaft?. <b>2015</b> , 10, 87-101		2
117	A review: Health promoting lactic acid bacteria in traditional Indonesian fermented foods. <b>2015</b> , 4, 47-55		83
116	Nutraceutical Supplements for Inflammatory Bowel Disease. <b>2015</b> , 30, 551-8		8
115	Reviewing clinical studies of probiotics as dietary supplements: probiotics for gastrointestinal disorders, <i>Helicobacter</i> eradication, lactose malabsorption and inflammatory bowel disease (IBD). <b>2015</b> , 171-197		
114	The human gut mycobiome: pitfalls and potentials--a mycologist's perspective. <b>2015</b> , 107, 1057-73		98
113	Diet and nutritional factors in inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 895-905	5.6	118
112	Adaptation of <i>Candida albicans</i> to commensalism in the gut. <b>2016</b> , 11, 567-83		36

111	In vitro investigation of <i>Debaryomyces hansenii</i> strains for potential probiotic properties. <b>2016</b> , 32, 141	22
110	Evaluation of antimicrobial activity and probiotic properties of wild-strain <i>Pichia kudriavzevii</i> isolated from frozen idli batter. <b>2016</b> , 33, 385-401	32
109	Specific probiotic dietary supplementation leads to different effects during remission and relapse in murine chronic colitis. <b>2016</b> , 7, 205-13	18
108	Clinical Uses of Probiotics. <i>Medicine (United States)</i> , <b>2016</b> , 95, e2658	1.8 104
107	Nutraceuticals in Gastrointestinal Disorders. <b>2016</b> , 109-122	3
106	Probiotics and prebiotics in ulcerative colitis. <b>2016</b> , 30, 55-71	65
105	Safety of Probiotic Bacteria. <b>2016</b> , 227-243	2
104	Immunity to Commensal Fungi: Detente and Disease. <b>2017</b> , 12, 359-385	59
103	Probiotics, Prebiotics, and Antibiotics in IBD. <b>2017</b> , 455-469	1
102	Global Food Security and Wellness. <b>2017</b> ,	3
101	Oral administration of yeast $\beta$ -glucan ameliorates inflammation and intestinal barrier in dextran sodium sulfate-induced acute colitis. <b>2017</b> , 35, 115-126	33
100	Spray-drying process preserves the protective capacity of a breast milk-derived <i>Bifidobacterium lactis</i> strain on acute and chronic colitis in mice. <b>2017</b> , 7, 43211	22
99	ESPEN guideline: Clinical nutrition in inflammatory bowel disease. <i>Clinical Nutrition</i> , <b>2017</b> , 36, 321-347	5.9 318
98	In vivo probiotic and antimicrobial photodynamic therapy as alternative therapies against cryptococcosis are ineffective. <b>2017</b> , 211, 169-173	5
97	Targeted delivery of probiotics to enhance gastrointestinal stability and intestinal colonisation. <b>2017</b> , 530, 224-229	60
96	Probiotics in Newborns and Children. <b>2017</b> , 64, 1271-1289	12
95	An Overview of Probiotic Research. <b>2017</b> , 293-357	1
94	Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. <b>2017</b> , 30, 191-231	41

93	Uso de probióticos en síndrome de intestino irritable y enfermedad inflamatoria intestinal: una revisión de la literatura. <b>2017</b> , 32, 141		
92	Treatment of Inflammatory Bowel Disease in Ulcerative Colitis. <b>2017</b> , 343-354		1
91	Nutritional Interventions in the Patient with Inflammatory Bowel Disease. <b>2018</b> , 47, 155-177		40
90	Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 26-42	6.1	107
89	Inflammatory Bowel Disease. <b>2018</b> , 501-516.e8		4
88	The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis. <i>Medicine (United States)</i> , <b>2018</b> , 97, e13792	1.8	33
87	Intestinal anti-inflammatory effect of the probiotic <i>Saccharomyces boulardii</i> in DSS-induced colitis in mice: Impact on microRNAs expression and gut microbiota composition. <i>Journal of Nutritional Biochemistry</i> , <b>2018</b> , 61, 129-139	6.3	56
86	Review of <i>Saccharomyces boulardii</i> as a treatment option in IBD. <i>Immunopharmacology and Immunotoxicology</i> , <b>2018</b> , 40, 465-475	3.2	15
85	Probiotics for inflammatory bowel diseases: a promising adjuvant treatment. <i>International Journal of Food Sciences and Nutrition</i> , <b>2019</b> , 70, 20-29	3.7	40
84	The Gut Microbiome. <b>2019</b> , 61-98		1
83	<i>Saccharomyces boulardii</i> alleviates ulcerative colitis carcinogenesis in mice by reducing TNF- $\alpha$ and IL-6 levels and functions and by rebalancing intestinal microbiota. <i>BMC Microbiology</i> , <b>2019</b> , 19, 246	4.5	50
82	Review article: fungal alterations in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 1159-1171	6.1	28
81	Unique genetic basis of the distinct antibiotic potency of high acetic acid production in the probiotic yeast var.. <i>Genome Research</i> , <b>2019</b> , 29, 1478-1494	9.7	24
80	The Efficacy of Probiotics, Prebiotic Inulin-Type Fructans, and Synbiotics in Human Ulcerative Colitis: A Systematic Review and Meta-Analysis. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	51
79	The enumeration of probiotic issues: From unavailable standardised culture media to a recommended procedure?. <i>International Dairy Journal</i> , <b>2019</b> , 96, 58-65	3.5	17
78	Fungal Probiotics: Opportunity, Challenge, and Prospects. <i>Fungal Biology</i> , <b>2019</b> , 101-117	2.3	5
77	Therapeutic Potential of Probiotics and Prebiotics. <b>2019</b> ,		2
76	Probiotic properties of intrinsic bacteria isolated from fermented polyherbal preparations of Indian Ayurveda. <i>LWT - Food Science and Technology</i> , <b>2019</b> , 103, 8-18	5.4	6

75	Saccharomyces cerevisiae. <b>2019</b> , 501-508		2
74	ESPEN practical guideline: Clinical Nutrition in inflammatory bowel disease. <i>Clinical Nutrition</i> , <b>2020</b> , 39, 632-653	5.9	82
73	Fermentation Product Did Not Attenuate Clinical Signs, but Psyllium Husk Has Protective Effects in a Murine Dextran Sulfate Sodium-Induced Colitis Model. <i>Current Developments in Nutrition</i> , <b>2020</b> , 4, nzaa159	9.4	3
72	Modulation of gut mucosal microbiota as a mechanism of probiotics-based adjunctive therapy for ulcerative colitis. <i>Microbial Biotechnology</i> , <b>2020</b> , 13, 2032-2043	6.3	15
71	Anti-Inflammatory and Gut Microbiota Modulatory Effect of Strain LDTM 7511 in a Dextran Sulfate Sodium-Induced Colitis Murine Model. <i>Microorganisms</i> , <b>2020</b> , 8,	4.9	8
70	Gut Microbiota beyond Bacteria-Mycobiome, Virome, Archaeome, and Eukaryotic Parasites in IBD. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	48
69	Antimicrobial mechanisms and applications of yeasts. <i>Advances in Applied Microbiology</i> , <b>2021</b> , 114, 37-72.	4.9	1
68	Ulcerative Colitis in Children and Adolescents. <b>2021</b> , 474-492.e8		0
67	The role of gut mycobiome in health and diseases. <i>Therapeutic Advances in Gastroenterology</i> , <b>2021</b> , 14, 17562848211047130	4.7	7
66	Food and Food Groups in Inflammatory Bowel Disease (IBD): The Design of the Groningen Anti-Inflammatory Diet (GrAID). <i>Nutrients</i> , <b>2021</b> , 13,	6.7	10
65	Development and characterization of enteric coated pectin pellets containing mesalamine and Saccharomyces boulardii for specific inflamed colon: In vitro and in vivo evaluation. <i>Journal of Drug Delivery Science and Technology</i> , <b>2021</b> , 62, 102393	4.5	3
64	Insights on the Critical Parameters Affecting the Probiotic Viability During Stabilization Process and Formulation Development. <i>AAPS PharmSciTech</i> , <b>2021</b> , 22, 156	3.9	3
63	In Vitro Probitotic Evaluation of with Antimicrobial Spectrum in a Model. <i>Foods</i> , <b>2021</b> , 10,	4.9	1
62	Probiotics, Prebiotics and Synbiotics in Inflammatory Bowel Diseases. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	17
61	Highlighting the Relevance of Gut Microbiota Manipulation in Inflammatory Bowel Disease. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	16
60	Role of Recent Therapeutic Applications and the Infection Strategies of Shiga Toxin-Producing. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2021</b> , 11, 614963	5.9	3
59	Probiotic Based Interventions for Improving Intestinal Health. <b>2021</b> , 29-56		
58	Nutraceuticals in gastrointestinal disorders. <b>2021</b> , 141-155		1

57	Prebiotics, Probiotics, Antibiotics, and Nutritional Therapies in IBD. <b>2011</b> , 123-150		2
56	Probiotics in Clinical Practice as Therapeutics Against Enteric Disorders. <b>2011</b> , 355-373		0
55	Ulcerative Colitis. <b>2010</b> , 1975-2013.e9		2
54	Therapeutic applications of probiotics in ulcerative colitis: An updated review. <i>PharmaNutrition</i> , <b>2020</b> , 13, 100194	2.9	16
53	Saccharomyces spp.. 51-60		0
52	Probiotics in inflammatory bowel disease: Does it work?. <i>World Journal of Meta-analysis</i> , <b>2020</b> , 8, 54-66	0.5	6
51	Modulation of intestinal inflammation by yeasts and cell wall extracts: strain dependence and unexpected anti-inflammatory role of glucan fractions. <i>PLoS ONE</i> , <b>2012</b> , 7, e40648	3.7	68
50	Inflammatory Bowel Diseases: The Role of Gut Microbiota. <i>Current Pharmaceutical Design</i> , <b>2020</b> , 26, 2951-2968	3.3	18
49	Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?. <i>Current Clinical Pharmacology</i> , <b>2020</b> , 15, 216-233	2.5	13
48	Probiyotikler, Prebiyotikler, Sinbiyotikler. <i>Sağlık Akademisi Kastamonu</i> , <b>2017</b> , 2, 71-71	0.2	4
47	Antimicrobial and probiotic properties of yeasts: from fundamental to novel applications. <i>Frontiers in Microbiology</i> , <b>2012</b> , 3, 421	5.7	173
46	Indications for 5-aminosalicylate in inflammatory bowel disease: is the body of evidence complete?. <i>World Journal of Gastroenterology</i> , <b>2006</b> , 12, 6115-23	5.6	30
45	Targeting intestinal microflora in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , <b>2006</b> , 12, 7225-6	5.6	2
44	Probiotics in inflammatory bowel disease. <b>2004</b> , 708-725		
43	Manipulation of enteric flora in ulcerative colitis. <i>World Journal of Gastroenterology</i> , <b>2005</b> , 11, 3327	5.6	
42	Drug Therapy of Inflammatory Bowel Disease in Fertile Women. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, S633-S639	0.7	0
41	Inflammatory Bowel Disease. <b>2007</b> , 541-554		
40	Probiotics in the Management of Inflammatory Bowel Diseases?. <i>American Journal of Gastroenterology</i> , <b>2007</b> , 102, 22-28	0.7	

- 39 Complementary Medicine & Mucosal Immunology -Recent Topics around Inflammatory Bowel Disease. *Japanese Journal of Complementary and Alternative Medicine*, **2008**, 5, 85-101 0
- 38 Probiotics in Ulcerative Colitis. **2009**, 181-194
- 37 Safety Issues of Probiotic Ingestion. **2009**, 69-80
- 36 Probiotics and prebiotics in the management of ulcerative colitis. *Food Science and Technology Bulletin*, **2009**, 5, 93-102
- 35 Application of Functional Dairy Products from IBS to IBD. **2009**, 375-393
- 34 The Role of the Gut Microbiota and Probiotics in Gastrointestinal Disease Prevention and Management. **2011**, 21-34
- 33 Probiotics, Prebiotics, and Antibiotics in Medical Management of Inflammatory Bowel Disease. **2012**, 517-534 1
- 32 Inflammatory Bowel Disease. **2012**, 464-474.e5
- 31 Pathophysiological responses from human gut microbiome. *World Journal of Translational Medicine*, **2014**, 3, 133 8
- 30 Functional Dairy Products. **2017**, 67-103 5
- 29 Probiotic Yeasts in Human Welfare. **2017**, 115-136
- 28 15 Inflammatory Bowel Disease. **2017**, 347-374
- 27 Pro-/Anti-Inflammatory Food Supplements. *Advances in Medical Diagnosis, Treatment, and Care*, **2020**, 142-168 0.2
- 26 Biomedical applications of ginsenosides nanoparticles synthesized using microbes. **2022**, 625-653 1
- 25 Probiotics in Inflammatory Bowel Diseases. **2006**, 121-125
- 24 Probiotic Therapy. **2008**, 351-361
- 23 Relevance of bacteria in the pathogenesis of inflammatory bowel disease. 21-29
- 22 Antibiotics and probiotics. 162-175



21	Probiotics in the management of inflammatory bowel disease. <i>MedGenMed: Medscape General Medicine</i> , <b>2005</b> , 7, 19		2
20	Dietary factors in the modulation of inflammatory bowel disease activity. <i>MedGenMed: Medscape General Medicine</i> , <b>2007</b> , 9, 60		1
19	Gut bacteria in health and disease. <i>Gastroenterology and Hepatology</i> , <b>2013</b> , 9, 560-9	0.7	101
18	Probiotics: current regulatory aspects of probiotics for use in different disease conditions. <b>2022</b> , 465-499		
17	Microbiome therapeutics: exploring the present scenario and challenges.. <i>Gastroenterology Report</i> , <b>2022</b> , 10, goab046	3.3	4
16	Development and Evaluation of Pectin Based Enteric Coated Microparticles Loaded with Mesalamine and for Management of Ulcerative Colitis. <i>Assay and Drug Development Technologies</i> , <b>2021</b> ,	2.1	2
15	alleviates DSS-induced intestinal barrier dysfunction and inflammation in humanized mice. <i>Food and Function</i> , <b>2021</b> ,	6.1	5
14	Recent trends in fungal dairy fermented foods. <b>2022</b> , 41-57		
13	Microbiota-targeted therapies in inflammation resolution.. <i>Seminars in Immunology</i> , <b>2022</b> , 101599	10.7	1
12	Gut microbiota and inflammatory bowel disease.. <i>WIREs Mechanisms of Disease</i> , <b>2022</b> , 14, e1540	0.3	2
11	The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies.. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 766126	4.9	3
10	The Fungal Gut Microbiome Exhibits Reduced Diversity and Increased Relative Abundance of Ascomycota in Severe COVID-19 Illness and Distinct Interconnected Communities in SARS-CoV-2 Positive Patients.. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2022</b> , 12, 848650	5.9	4
9	Probiotic Yeast <i>Saccharomyces</i> : Back to Nature to Improve Human Health. <i>Journal of Fungi (Basel, Switzerland)</i> , <b>2022</b> , 8, 444	5.6	4
8	IL-22 and <i>Lactobacillus delbrueckii</i> mitigate alcohol-induced exacerbation of DSS-induced colitis.		
7	Prebiotic Immunomodulators to Enhance Mucosal Immunity and to Reduce Mass Use of Antibiotics. <b>2022</b> , 419-447		0
6	Inflammatory bowel disease therapeutic strategies through the modulation of the microbiota: how and when to introduce pre-, pro-, syn- or postbiotics?.		1
5	Probiyotiklerin Genel Özellikleri ve Sağlık Üzerine Etkileri.		0
4	Fungal infections and the fungal microbiome in hepatobiliary disorders. <b>2022</b> ,		1

- 3 Could paraprobiotics be a safer alternative to probiotics for managing cancer chemotherapy-induced gastrointestinal toxicities?. 55,
- 2 Immunometabolism and microbial metabolites at the gut barrier: lessons for therapeutic intervention in Inflammatory Bowel Disease. **2023**,
- 1 Fermented foods, prebiotics, and probiotics. **2023**, 239-263